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Acetaminophen, also known as APAP or paracetamol, is one of the most widely used
analgesics (pain reliever) and antipyretics (fever reducer). According to the U.S. Food and
Drug Administration, currently there are 235 approved prescription and over-the-counter
drug products containing acetaminophen as an active ingredient. When used as directed,
acetaminophen is very safe and effective; however when taken in excess or ingested with
alcohol hepatotoxicity and irreversible liver damage can arise. In addition to well known use
pain relief and fever reduction, recent laboratory and pre-clinical studies have demonstrated
that acetaminophen may also have beneﬁcial effects on blood glucose levels, skeletal muscle function, and potential use as cardioprotective and neuroprotective agents. Extensive
laboratory and pre-clinical studies have revealed that these off-label applications may be
derived from the ability of acetaminophen to function as an antioxidant. Herein, we will
highlight these novel applications of acetaminophen, and attempt, where possible, to highlight how these ﬁndings may lead to new directions of inquiry and clinical relevance of other
disorders.
Keywords: acetaminophen, antioxidant, hyperglycemia, skeletal muscle, cardiac protection

INTRODUCTION
Acetaminophen (N-Acetyl-4-aminophenol) also known as“APAP”
or “paracetamol” is one of the most widely used medicines in
the United States. According to the data from IMS Health, ∼24.6
billion doses of acetaminophen were sold in 2008. The market
demand for acetaminophen is growing. Recent data has demonstrated a 28% growth in the market sales of acetaminophen
between 2004 and 2008 with sales approaching approximately $2.6
billion in 2008 alone (Data from IMS Health).
Acetaminophen exhibits both analgesic and antipyretic properties and has been widely used as an active ingredient in many
approved drugs. According to the U.S. Food and Drug Administration (FDA), 479 drugs contain acetaminophen (Table 1). As of
August 2011, 235 out of the 479 acetaminophen-containing drugs
exhibit active approval status, which include 214 prescription
drug products owned by 31 companies and 21 over-the-counter
(OTC) drug products produced by nine companies (Tables 1
and 2). Given its wide use and easy availability, scientists have
recently begun to examine acetaminophen for off-label applications. Herein, we will investigate these potential applications,
and attempt, where possible, to highlight how these ﬁndings may
lead to new directions of inquiry and clinical relevance of other
disorders.

CHRONIC ACETAMINOPHEN INGESTION CAN IMPROVE
BLOOD GLUCOSE CONTROL
Although a toxic dose of acetaminophen (3 h following 500 mg
APAP/kg body weight) can rapidly induce hyperglycemia (Hinson et al., 1984) and acute liver failure secondary to clinical
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acetaminophen overdose can further impair the peripheral uptake
of glucose (Clark et al., 2001), recent animal studies have demonstrated that acetaminophen, when taken at lower dosages (20–
30 mg/kg body weight) exhibits an ability to lower blood glucose
levels in several animal disease models, including diabetes, high-fat
(HF) diet induced obesity, and aging.
Using a streptozotocin (STZ)-induced diabetic mice model,
Shertzer et al. (2008) showed that acetaminophen at 20 mg/kg
body weight is able to normalize STZ-induced increases in blood
glucose levels. This effect appears to be associated with protection
against STZ-induced destruction of pancreatic beta-cells given the
ﬁnding that acetaminophen injection appears to be associated with
the maintenance of pancreatic insulin synthesis (Shertzer et al.,
2008). Like that observed in the STZ model, acetaminophen at 20
or 30 mg/kg body weight has also been reported to prevent hyperglycemia in animals fed a HF diet (Shertzer et al., 2008, 2010).
In addition to preventing hyperglycemia, acetaminophen ingestion is also associated with the restoration of fasting insulin levels,
improvements in glucose tolerance, and an increased ability of the
HF-fed mice to boost blood insulin levels after a glucose challenge
(Shertzer et al., 2008, 2010). Although the exact mechanism(s)
remains unclear, these effects, like that seen in the rat STZ model,
have been postulated to arise from improvements in pancreatic
insulin synthesis/secretion.
Research using both humans and animal models have demonstrated that the incidence of insulin resistance increases with
age (Houmard et al., 1995; Wu et al., 2009a). Wu et al. (2009a)
using Fisher 344 × Brown Norway (F344BN) aging rat model
have shown that age-associated increases in blood glucose can
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Table 1 | Approved drug products containing acetaminophen as an
active ingredient.
Approved drugs

Companies

Prescription drug products (Rx)

214

31

Over-the-counter drug products (OTC)

21

9

Discontinued drug products

244

60

Total

479

100

Table 2 | Over-the-counter drug products (OTC) containing
acetaminophen.
Company name

Drug name

Actavis mid Atlantic

Infants’ Feverall; acetaminophen.

G and W labs

Acephen

McNeil consumer healthcare

Tylenol

Novartis

Excedrin (migraine); tavist

Ohm labs

Acetaminophen

Perrigo

Acetaminophen; acetaminophen,

Polymedica

Neopap

Ranbaxy

Acetaminophen

Schering plow

Drixoral plus

allergy/sinus/headache

aspirin and caffeine

Data source: the orange book from FDA.

be corrected by chronic acetaminophen treatment at the dosage
of 30 mg/kg body weight. It has been postulated that this
effect was predicated, at least in part, on the ability of acetaminophen to diminish age-related losses in amount of muscle glucose transporter-4 (Glut4) expression (Wu et al., 2009a).
Further study demonstrated that acetaminophen treatment was
also associated with an attenuation of muscle reactive oxygen
species (ROS) levels and in the amount of proteins that become
oxidatively modiﬁed (Wu et al., 2009a). It has been shown
that prolonged mitogen activated protein kinase (MAPK) activation is associated with decreased Glut4 expression (Fujishiro
et al., 2001; Carlson et al., 2003) and Glut4 translocation in
response to insulin (Bandyopadhyay et al., 2001; Izawa et al., 2005;
D’Alessandris et al., 2007). Interestingly, works done by Wu et al.
(2009a) showed that acetaminophen treatment could normalize
the marked increases in p38- and ERK–MAPK activation seen in
aged muscle. Taken together, these ﬁndings suggests that acetaminophen might function to improve blood glucose levels by
employing multiple mechanisms including decreases in intracellular ROS levels, diminished aging-associated MAPK hyperphosphorylation and by increasing muscle Glut4 expression (Wu et al.,
2009a).
LONG TERM ACETAMINOPHEN INGESTION CAN IMPROVE SKELETAL
MUSCLE STRUCTURE AND FUNCTION

In addition to the beneﬁcial effect of acetaminophen on relieving muscle soreness and pain (Prior et al., 2011), recent studies
have suggested that acetaminophen can improve aged skeletal
muscle structure and function (sarcopenia). Wu et al. (2009b)

ﬁrstly reported that chronic acetaminophen treatment at 30 mg/kg
body weight is able to decrease the amount of aging-associated
myocyte apoptosis and increase myocyte size (muscle ﬁber cross
sectional area), with this latter effect occurring most likely associated with an increase in myosin and actin expression in aged
muscle. These effects are believed to be mediated, at least in part,
via reductions in the amount of oxidative and nitrosative stress
as acetaminophen intervention lowers the amount of superoxide
and the abundance of oxidatively modiﬁed proteins (Wu et al.,
2009a). It also appears that acetaminophen treatment reduces
the phosphorylation of eukaryotic initiation factor 2a (eIF2a;
Wu et al., 2010), a key protein translational factor which when
phosphorylated in response to stress leads to the inhibition of
protein translational initiation (Kimball, 1999). Other data has
demonstrated that acetaminophen can decrease muscle reactive
nitrogen species (RNS) as evidenced by reduced expression of
inducible NOS (iNOS) and S-nitrosylation of Akt (Wu et al.,
2009b). The Akt/protein kinase B is critical regulator of cellular
homeostasis and functions to control cellular anabolism (protein synthesis, glucose uptake, and metabolism) and cell fate
(proliferation, apoptosis; Wu et al., 2011). Akt S-nitrosylation
impairs Akt kinase activity (Carvalho-Filho et al., 2005; Yasukawa
et al., 2005; Wu et al., 2009b), which if not corrected can lead
to a dysregulation of Akt signaling. Importantly, the restoration
of Akt function by acetaminophen is associated with improvements in protein translational signaling [increased phosphorylation/activation of S6 ribosomal protein (Ser235/236) and translation initiation factor eIF4E (Ser209)], increases in the amount of
muscle Glut4, myosin, and actin, along with a decrease in myocyte
apoptosis and the prevention of age-associated hyperglycemia
(Wu et al., 2009a,b, 2010).
The positive effects of acetaminophen on skeletal muscle structure and function have also been proved in other experimental
sitting. Shertzer et al. (2008) reported that acetaminophen is able
to prevent HF diet induced decreases in lean muscle volume and
body water retention. Trappe et al. (2011) demonstrated during
12 weeks of knee extensor progressive resistance exercise training
that acetaminophen (4 g/day) can increase exercise-induced muscle (quadriceps) hypertrophy and strength in older adults when
compared to that seen with placebo, although muscle (vastus lateralis) protein content, muscle water content, and myosin heavy
chain distribution did not increase. Interestingly, increased muscle volume and strength by acetaminophen appears not to be
mediated by cyclooxygenase (COX), as the expression of COX1 and COX-2 was not changed with acetaminophen consumption
(Trappe et al., 2011). Importantly, acetaminophen at 4 g/day for
12 weeks when used in combination with resistance training did
not alter blood creatinine and ALT levels (Trappe et al., 2011), a
ﬁnding which suggests that this dosage does not cause liver or
kidney damage. Interestingly, the effect of acetaminophen and
exercise combination appears dependent on type of exercise as
acetaminophen has been reported to suppress the protein synthesis response in skeletal muscle after eccentric resistance exercise
(Trappe et al., 2002), which appears to be mediated through
decreasing exercise-induced PGF(2alpha) expression and hence
affecting the anabolic response of muscle to eccentric resistance
exercise (Trappe et al., 2001). Whether a similar ﬁnding exists
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for other types of exercise modalities (e.g., aerobic) is currently
unclear.

ACETAMINOPHEN POSSESSES CARDIOPROTECTIVE AND
NEUROPROTECTIVE PROPERTIES
Clinical studies have suggested that the risk for major cardiovascular events will be increased if acetaminophen is taken frequently
(≥22 days/month) or at high doses (15 tablets/week; Chan et al.,
2006). Nonetheless, when used properly, acetaminophen has been
shown to exhibit cardioprotective effects. Using an isolated guinea
pig heart model, several studies have shown that acetaminophen
(0.35 mM) can increase coronary vascular resistance and positive inotropy (Merrill et al., 2001), attenuate ischemia-reduced
monophasic action potentials (Merrill and Goldberg, 2001), and
improve left ventricular contractility (rate of developed pressure)
during post ischemia–reperfusion (Merrill et al., 2001; Merrill,
2002). Further examination using electron microscopy has suggested that acetaminophen can preserve left ventricular myoﬁbrillar ultrastructure in the reperfused myocardium, including protection against ischemia/reperfusion-induced diffused and blurred
Z lines, the presence of contraction bands, and swollen, sparsely
packed mitochondria (Merrill et al., 2001). Using two dog models of ventricular arrhythmias induced by regional myocardial
ischemia/reperfusion or ouabain (25 μg/kg), Merrill et al. (2007)
demonstratedan anti-arrhythmic effect for acetaminophen, and
found that acetaminophen (15 mg/kg, i.v.) signiﬁcantly reduce the
number of ventricular ectopic beats during ischemia and reperfusion, the amount of ouabain-induced ventricular premature beats,
ventricular salvo, ventricular bigeminy, and non-sustained ventricular arrhythmia. In the iron-overloaded gerbil, Walker et al.
(2007) have demonstrated that acetaminophen is able to prevent
iron overload-induced cardiac structural and functional changes,
including alterations in cardiac rhythm, ventricular distension,
reductions in left ventricular ejection fraction, decreases in fractional shortening, and decreases in mortality (Walker et al., 2009).
Mauger et al. (2010) reported that ingestion of acetaminophen
(1.5 g) can improve the performance of a 10-mile cycle time trial
(TT) with no difference in exertion or perceived pain, and that
cyclists who ingested acetaminophen had a higher mean power
output and heart rate. Merrill et al. (2004) using a myocardial
infarction dog model showed that acetaminophen at 30 mg/kg
body weight is able to decrease infarct size. These researchers
also showed acetaminophen treatment can reduce cardiac damage, including swollen mitochondria and fragmented nucleus
(Merrill et al., 2004). Conversely, others using different animal
models did not show beneﬁcial effects on infarct size in nonpreconditioned rats (Dai and Kloner, 2003) or in coronary artery
occlusion/reperfusion rabbits (Hale and Kloner, 2004), however all
suggest that acetaminophen is a safe drug in the postmyocardial
infarction setting (Dai and Kloner, 2003; Hale and Kloner, 2004;
Leshnower et al., 2006). Further studies deﬁning detailed conditions are needed to verify the protective effect of acetaminophen
on infarct size.
It has also been reported that acetaminophen has neuroprotective effects. Maharaj et al. (2004) reported that acetaminophen (0.25–1 mM) treatment ex vivo can inhibit cyanideinduced superoxide anion generation and lipid peroxidation
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in rat brain homogenates. Further animal study has suggested
the acetaminophen (100 mg/kg/day, i.p.) can inhibit quinolinic
acid (QA)-induced lipid peroxidation, superoxide anion generation, and cell damage in the rat hippocampus (Maharaj et al.,
2006). Naziroglu et al. (2009) also reported acetaminophen
(5–100 mg/kg) can reduce brain and microsomal lipid peroxidation, while it also increases brain vitamin E levels and microsomal glutathione peroxidase (GSH-Px) activity. In addition, Bisaglia et al. (2002) used rat primary hippocampal neurons and
rat pheochromocytoma cells demonstrated that acetaminophen
(100 μM) can protect against amyloid beta-fragment-induced
impairment of mitochondrial redox activity, increases in phospholipid peroxidation, and apoptotic nuclear fragmentation, suggesting a possible therapeutic effect of acetaminophen on Alzheimer’s
disease.

ACETAMINOPHEN EXHIBITS POTENT ANTIOXIDANT
ACTIVITY
It is well known that acetaminophen overdose can lead to oxidative stress and induce hepatic and renal damage (Ghosh et al.,
2010; Agarwal et al., 2011). Acetaminophen is initially metabolized in the liver, and generates the toxic metabolite, N -acetyl-pbenzoquinone imine (NAPQI). NAPQI can be efﬁciently detoxiﬁed by glutathione (GSH) which is an important cellular antioxidant for detoxiﬁcation of drugs and foreign chemicals. When
overdosed with acetaminophen, intracellular glutathione can be
depleted within 1–4 h (Al-Turk and Stohs, 1981; Porubek et al.,
1987; Lores Arnaiz et al., 1995), resulting in accumulation of
intracellular reactive oxygen and nitrogen species (ROS/RNS), and
oxidative/nitrosative stress will occur. The over-produced NAPQI
can covalently bind to the cysteinyl thiol groups of cellular proteins
and form protein-(cystein-S-yl)-APAP adducts (Hoffmann et al.,
1985), which may impair protein function. Given this mechanism,
antioxidant therapy using N -acetylcysteine (NAC) is commonly
used to attenuate acetaminophen-induced hepatotoxicity.
Interestingly, extensive animal and in vitro studies have suggested that acetaminophen possesses remarkable antioxidant
properties when used within the therapeutic dosage. Acetaminophen is phenolic in structure with a substituent at the para
position relative to the hydroxyl group (Figure 1) which allows
it to react with reactive species (Dinis et al., 1994; Shertzer et al.,
2008). For example, Shertzer et al. (2008) using cell-free assay
systems demonstrated that acetaminophen at a concentrations
of 2–10 μM is able to directly scavenge reactive oxygen. Nam
et al. (2009) found that acetaminophen has higher reactivity

FIGURE 1 | Structure of acetaminophen (N-Acetyl-4-aminophenol). The
phenolic structure with a substituent at the para position relative to the
hydroxyl group allows acetaminophen to react with reactive species and
possesses antioxidant activity.
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with peroxyl radicals than many widely used phenolic antioxidants, including ubiquitous butylated hydroxytoluene (BHT).
Other in vitro studies showed that acetaminophen can signiﬁcantly
inhibit hemoprotein-induced lipid peroxidation by its ability to
reducing ferryl heme to its ferric state and the quenching globin radicals (Boutaud et al., 2010). Acetaminophen has also be
shown to reduce the degree of low-density lipoproteins (LDL)
hydroperoxides induced by Cu2+ ions (Ozsoy and Pabuccuoglu,
2007) or myeloperoxidase in presence of nitrite and hydrogen
peroxide (Chou and Greenspan, 2002). Several studies have also
demonstrated that acetaminophen can directly scavenge peroxynitrite (Van Dyke et al., 1998; Rork et al., 2006; Schildknecht
et al., 2008), a highly reactive oxidant and nitrating agent that
can oxidize lipids, proteins, and nucleic acids. Nam et al. (2009)
showed that when nitrogen is incorporated into the phenolic
ring the antioxidant activity of acetaminophen is greatly reduced
and that this ﬁnding seems to be associated with increased O–
H bond dissociation enthalpy. However, this structural change
increases the efﬁcacy of acetaminophen to act as an inhibitor
of lipid hydroperoxide biosynthesis by soybean lipoxygenases1 (sLOX-1) (Nam et al., 2009) and further evidences suggested
that altered acidity of the phenolic O–H may lead to chelation of
the catalytic non-heme iron atom in sLOX-1 (Nam et al., 2009).
Taken together, it appears that the structure of the acetaminophen
phenolic ring is critical for its pharmacological and antioxidant
properties.
Ex vivo and in vivo animal studies have suggested that acetaminophen can effectively reduce ROS/RNS in multiple tissue
types. Back in 1983, DuBois et al. (1983) reported that acetaminophen had antioxidant effects in the rat liver. Shertzer
et al. (2008) also showed that acetaminophen (20 mg/kg) can
decrease liver mitochondrial H2 O2 formation in both control and HF diet fed mice. Wu et al. (2009a,b, 2010) demonstrated that acetaminophen treatment at 30 mg/kg for 6 months
can attenuate aging-increased skeletal muscle ROS content, the
amount of proteins that are oxidatively modiﬁed, and protein
S-nitrosylation, suggesting acetaminophen can decrease oxidative/nitrosative stress during aging. Using a rhabdomyolysisinduced renal failure animal model, Boutaud et al. (2010) showed
that acetaminophen (100 mg/kg, i.p.) can signiﬁcantly decrease
myoglobin-derived radical species and that this ﬁnding was associated with reduced renal damage and improved renal function.
Usinga HF fed animal model, Shertzer et al. (2010) demonstrated
that acetaminophen (30 mg/kg/day) was able to inhibit production of reactive oxygen species (at least partially via inhibition
of NADPH oxidase activity) and lipid peroxidation in white adipose tissue (WAT) which improved glucose tolerance and insulin
sensitivity in HF animals.
Although not yet well understood, the cardioprotective effects
of acetaminophen seem to relate to its antioxidant property
(Merrill and Goldberg, 2001; Merrill et al., 2001; Merrill, 2002;
Rork et al., 2006; Hadzimichalis et al., 2007; Walker et al.,
2007, 2009; Kakarla et al., 2010). Using Langendorff-perfused
guinea pig hearts, Hadzimichalis et al. (2007) reported that acetaminophen (0.35 mM) can reduce mitochondrial swelling, and
inhibit the mitochondrial permeability transition pore-induced
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FIGURE 2 | Summary of acetaminophen therapeutic effects. In addition
to the clinically proven analgesic/antipyretic properties, laboratory and
pre-clinical studies demonstrated that acetaminophen has other beneﬁcial
effects that would increase clinical application of acetaminophen. However,
clinical studies are needed to ensure its safety, efﬁciency, and proper
dosage.

apoptotic pathway and mitochondrial cytochrome C release
in heart with induced low-ﬂow global myocardial ischemia.
Merrill et al. (2001) demonstrated that acetaminophen can signiﬁcantly attenuate the burst of hydroxyl radicals during the
ﬁrst 10 min of reperfusion, and block 3-morpholinosydnominine
(SIN-1)-induced peroxynitrite generation. Kakarla et al. (2010)
have found that chronic acetaminophen treatment at 30 mg/kg
body weight is able to attenuate aging-associated increases in
cardiac oxidative (superoxide) and nitrosative (protein nitrotyrosylation) stresses, caspase-3 activation, and apoptosis in F344BN
rats. Rork et al. (2006) reported that acetaminophen (0.35 mM)
can reduce peroxynitrite in the isolated guinea pig myocardium
and that this ﬁnding was associated with an attenuated activation
of MMP-2 and decreased cleavage of troponin I (TnI) following
ischemia/reperfusion. Therefore, cardioprotective effects of acetaminophen are at least partially mediated by reducing tissue reactive
oxygen and nitrogen species.

CONCLUSION AND PERSPECTIVES
Recent experimental data suggests that acetaminophen may
have several remarkable effects other than its well known analgesic/antipyretic properties. Thus far, acetaminophen has been
shown to improve blood glucose control, improve skeletal muscle
structure and function in the aged, and that this agent exhibits
cardioprotective and neuroprotective effects (Figure 2). Current
laboratory and pre-clinical studies have revealed that many of these
ﬁndings can be linked to its incredible antioxidant properties. It is
also worth noting that since acetaminophen overdose or ingestion
with alcohol can cause hepatotoxicity and death, well controlled
clinical studies must be conducted to ensure the safety and efﬁciency of acetaminophen before its clinical application for off-label
application.
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